Serina Therapeutics (SER) AI Stock Analysis

• Market Cap: $54.12M
• Dividend Yield: N/A
• Average Volume (3M): 9.17K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.64
• Revenue Growth: 34.04%
• EPS Growth: 55.34%
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.49
• Shares Outstanding: 9,967,381
• 10 Day Avg. Volume: 3,128
• 30 Day Avg. Volume: 9,172
• PEG Ratio: -0.60
• Price to Book (P/B): 32.52
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.84
• Enterprise Value/Market Cap: 0.97
• Enterprise Value/Revenue: 119.26
• Enterprise Value/Gross Profit: -1.09K
• Enterprise Value/Ebitda: -2.47
• 1Y Price Target: $11.00
• Price Target Upside: 102.58% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Serina Therapeutics' overall stock score is primarily hindered by severe financial challenges, including declining revenue, high liabilities, and negative cash flow. While there is some short-term technical momentum and positive corporate developments, these do not offset the fundamental financial concerns. The valuation remains weak due to negative earnings, contributing to a low overall score.

Positive Factors

Convenience and Patient Comfort

The enFuse device delivers SER-252 in a significantly more convenient manner compared to alternative infusion systems, enhancing patient comfort.

Market Potential

SER-252 has the potential to become the best-in-class drug in advanced Parkinson's Disease.

Regulatory Approval

The discussion highlighted the company's clear vision of SER-252's path for regulatory approval, with a potential for 505(b)2 and associated reductions in timelines and costs, and their confidence they can reach the clinical benchmarks required to be approved.

Negative Factors

Competition

63% of patients treated with competing product ONAPGO experience infusion site reactions, highlighting potential challenges in the market.

Financial Needs

Serina will require additional capital to support development, as current cash is expected to last through 2Q25.

Serina Therapeutics Business Overview & Revenue Model

Company Description

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.

How the Company Makes Money

Serina Therapeutics makes money through licensing agreements and partnerships with pharmaceutical companies interested in utilizing its proprietary POZ technology to enhance their drug products. These collaborations often involve upfront payments, milestone payments, and royalties on sales of successfully commercialized products. Additionally, Serina may engage in research and development contracts, where they apply their technology to develop customized drug delivery solutions for clients, generating revenue through service fees. Partnerships with larger pharmaceutical companies also provide strategic funding, supporting the company's ongoing research and development efforts.

Serina Therapeutics Financial Statement Overview

Summary

Serina Therapeutics is facing severe financial challenges across all key financial statements. The income statement reflects substantial losses and declining revenue, the balance sheet is under strain due to high liabilities and negative equity, and cash flow issues point to operational inefficiencies. These factors collectively suggest a need for strategic restructuring or significant operational improvements to ensure future viability.

Income Statement

Serina Therapeutics has experienced significant volatility in revenue and profitability. The TTM data shows a drastic decline in revenue, leading to negative gross and net profit margins. This indicates severe inefficiencies and a struggle to generate sufficient income. Previous periods also reflect a trend of high losses, with EBIT and EBITDA margins persistently underperforming.

Balance Sheet

The balance sheet shows a concerning financial structure with a very low equity base and high liabilities, resulting in a negative equity in some periods. The debt-to-equity ratio is not ideal, and the return on equity is not calculable due to negative equity. This suggests high financial risk and instability.

Cash Flow

The cash flow statement highlights consistent negative free cash flow, indicating operational challenges. The operating cash flow is significantly negative, suggesting that the company struggles to generate cash from its core activities. Despite some positive financing activities, the overall cash flow position is weak.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
65.00K	56.00K	142.00K	500.00K	3.04M	54.00K
	Gross Profit
-48.00K	-138.00K	-29.00K	355.00K	2.89M	-1.23M
	EBIT
-20.59M	-17.05M	-9.96M	-2.27M	-1.63M	-10.41M
	EBITDA
-553.00K	-10.49M	-9.78M	-2.60M	-1.59M	-8.74M
	Net Income Common Stockholders
-939.00K	-11.14M	-14.80M	-2.68M	-1.26M	-10.87M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
645.00K	3.67M	345.00K	532.23K	1.31M	527.00K
	Total Assets
3.24M	6.72M	11.96M	858.04K	1.84M	3.92M
	Total Debt
18.12M	268.00K	4.37M	1.81M	398.17K	6.30M
	Net Debt
17.48M	-3.40M	4.02M	1.28M	83.33K	5.77M
	Total Liabilities
20.56M	6.22M	6.61M	38.64M	36.95M	9.32M
	Stockholders Equity
-17.21M	641.00K	5.47M	-37.78M	-35.11M	-5.12M
Cash Flow		Free Cash Flow
-19.89M	-17.16M	-7.80M	-2.09M	-2.36M	-7.84M
	Operating Cash Flow
-19.88M	-17.14M	-7.80M	-2.08M	-2.25M	-7.82M
	Investing Cash Flow
-8.00K	-22.00K	-10.00M	980.94K	823.32K	-20.00K
	Financing Cash Flow
15.40M	13.21M	17.50M	1.31M	1.08M	5.96M

Serina Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5.43
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SER, the sentiment is Neutral. The current price of 5.43 is below the 20-day moving average (MA) of 5.73, above the 50-day MA of 5.24, and below the 200-day MA of 5.80, indicating a neutral trend. The MACD of 0.08 indicates Positive momentum. The RSI at 47.52 is Neutral, neither overbought nor oversold. The STOCH value of 38.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SER.

Serina Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.19B	3.04	-44.64%	2.82%	16.45%	-0.53%
PDSB	50 Neutral	$66.74M	―	-119.22%	―	―	25.51%
KRON	46 Neutral	$41.03M	―	-59.49%	―	21.15%	46.44%
GANX	46 Neutral	$57.93M	―	-290.21%	―	-100.00%	44.28%
SER	38 Underperform	$54.12M	―	45.59%	―	34.04%	55.34%
VRCA	38 Underperform	$59.55M	―	-1546.58%	―	-19.45%	31.22%
STRO	35 Underperform	$76.99M	―	-679.15%	―	-56.88%	-57.57%

Serina Therapeutics Corporate Events

Serina Therapeutics Unveils Breakthrough in LNP Technology

On April 15, 2025, Serina Therapeutics announced that its Chief Development Officer, Dr. Randall Moreadith, presented at the LNP Formulation & Process Development Summit in Boston. The presentation highlighted a significant advancement in lipid nanoparticle (LNP) technology, where the company has identified a PEOZ-lipid capable of replacing the PEG-lipid in standard LNP formulations. This breakthrough addresses the high incidence of anaphylaxis associated with PEG-lipids in mRNA vaccines and other therapies, potentially improving safety and efficacy for patients.

Spark’s Take on SER Stock

According to Spark, TipRanks’ AI Analyst, SER is a Neutral.

Serina Therapeutics’ overall stock score is primarily hindered by severe financial challenges, including declining revenue, high liabilities, and negative cash flow. Although there is some short-term technical momentum, the valuation is weak due to negative earnings. Positive corporate developments and strategic initiatives are noted but do not offset the fundamental financial concerns.

To see Spark’s full report on SER stock, click here.

Serina Therapeutics Secures $5M for Parkinson’s Treatment

On April 8, 2025, Serina Therapeutics announced a $5 million private placement of securities to support the development of SER-252, its lead candidate for advanced Parkinson’s disease. This funding will aid in initiating a Phase 1 clinical trial for SER-252, which uses Serina’s POZ technology to provide continuous dopaminergic stimulation, potentially offering significant benefits to patients.

Spark’s Take on SER Stock

According to Spark, TipRanks’ AI Analyst, SER is a Neutral.

Serina Therapeutics’ overall stock score is primarily hindered by severe financial challenges, including declining revenue, high liabilities, and negative cash flow. Although there is some short-term technical momentum, the valuation is weak due to negative earnings. Positive corporate developments and strategic initiatives are noted but do not offset the fundamental financial concerns.

To see Spark’s full report on SER stock, click here.

Serina Therapeutics CEO to Present at Innovation Conference

On April 7, 2025, Serina Therapeutics announced that its CEO, Steve Ledger, will present at the Jones Healthcare and Technology Innovation Conference on April 9, 2025. The presentation will highlight the company’s advancements, particularly the POZ Platform and the upcoming clinical trial of SER-252 for Parkinson’s disease. This announcement underscores Serina’s strategic positioning in the biotechnology sector and its potential impact on treatment options for Parkinson’s disease, with SER-252 projected to achieve significant market success.

Spark’s Take on SER Stock

According to Spark, TipRanks’ AI Analyst, (SER) is a Neutral.

Serina Therapeutics’ stock score is primarily hindered by its severe financial challenges, including declining revenue, high liabilities, and negative cash flow. While there is some short-term technical momentum, the overall valuation is weak due to negative earnings. Positive corporate developments and strategic initiatives are noted but do not offset the fundamental financial concerns.

To see Spark’s full report on (SER) stock, click here.

Serina Therapeutics Unveils Breakthrough in POZ-Lipid Technology

On March 24, 2025, Serina Therapeutics announced that its Chief Development Officer, Randall Moreadith, presented new data at the American Chemistry Society Spring 2025 Meeting. The presentation highlighted the non-immunogenic profile of Serina’s POZ-lipid technology, which did not trigger an antibody response in rats, unlike the commonly used PEG-lipid standards. This discovery could lead to safer and more effective lipid nanoparticle formulations for gene therapy and RNA-based medicines, potentially impacting the development of treatments that avoid adverse immune reactions.